Luye Pharma (02186.HK) announced that several innovative products of the group have successfully been included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceuticals Catalogue (2024)". This includes the first-time inclusion of Ruoxinlin, the addition of Baituowei for breast cancer indications, and Helipu's inclusion in the regular catalogue. The new national health insurance pharmaceuticals catalogue will officially take effect on January 1, 2025. (vc/w)

~